This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
DND1 Polyclonal Antibody
catalog :
PA5-41963
quantity :
100 uL
price :
US 464.00
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human
application :
western blot, immunohistochemistry, immunohistochemistry - paraffin section
product information
Product Type :
Antibody
Product Name :
DND1 Polyclonal Antibody
Catalog # :
PA5-41963
Quantity :
100 uL
Price :
US 464.00
Clonality :
Polyclonal
Purity :
Affinity Chromatography
Host :
Rabbit
Reactivity :
Human
Applications :
Immunohistochemistry (Paraffin): 1:100, Western Blot: 0.2-1 ug/mL
Species :
Human
Isotype :
IgG
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Description :
DND1 contains 2 RRM (RNA recognition motif) domains. It may play a role during primordial germ cell (PGC) development. However, DND1 does not seem to be essential for PGC migration.
Immunogen :
Synthetic peptide directed towards the C-terminal of human DND1 (aa 286-335).
Format :
Liquid
Applications w/Dilutions :
Immunohistochemistry (Paraffin): 1:100, Western Blot: 0.2-1 ug/mL
Aliases :
BC034897; dead end homolog 1; dead end homolog 1 (zebrafish); dead end protein homolog 1; DND microRNA-mediated repression inhibitor 1; Dnd1; MGC34750; Rbms4; RNA-binding motif, single-stranded-interacting protein 4; Ter; teratoma
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments